Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

 Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer

Read more at globenewswire.com